Read by QxMD icon Read

Dyskinesia anxiety

Sara G Lutz, Jeffrey D Holmes, Emily A Ready, Mary E Jenkins, Andrew M Johnson
Up to 40% of all individuals with Parkinson's disease (PD) are estimated to experience anxiety that interferes with daily functioning. This article describes research regarding the presentation of anxiety in PD and the influence anxiety has on participation in this population. A scoping review identified 1,635 articles, of which 49 met the inclusion criteria. This review identified that anxiety in PD is often associated with a range of clinical correlates related to demographic and clinical characteristics (age, gender, disease stage, duration, progression), motor symptoms (tremor, bradykinesia, dystonia, freezing of gait, symptom severity), treatment-related complications (on/off fluctuations, on with dyskinesia, unpredictable off), and non-motor symptoms (sleep abnormalities, fatigue, cognitive impairment, depression)...
July 2016: OTJR: Occupation, Participation and Health
Virginie Woisard, Xuelai Liu, Marie Christine Arné Bes, Marion Simonetta-Moreau
Data, regarding the use of botulinum toxin (BT-A) in laryngeal dyspnea, are scarce, coming from some cases reports in the literature, including Vocal fold paralysis, laryngeal dystonia, vocal cord dysfunction also called paradoxical motion of the vocal fold (PMVF), and post-neuroleptic laryngeal dyskinesia. There is no consensus regarding the muscles and the doses to inject. The aim of this study is to present a retrospective review of patients treated in our ENT Department by BT-A injection in this indication...
September 6, 2016: European Archives of Oto-rhino-laryngology
D Hirjak, P A Thomann, G Northoff, K M Kubera, R C Wolf
The clinical picture of catatonia includes impressive motor phenomena, such as rigidity, dyskinesia, festination, negativism, posturing, catalepsy, stereotypies and mannerisms, along with affective (e. g. aggression, anxiety, anhedonism or emotional lability) and behavioral symptoms (e.g. mutism, autism, excitement, echolalia or echopraxia). In English speaking countries seven catatonia rating scales have been introduced, which are widely used in clinical and scientific practice. In contrast, only one validated catatonia rating scale is available in Germany so far...
June 21, 2016: Der Nervenarzt
Márton Kovács, Attila Makkos, Zsuzsanna Aschermann, József Janszky, Sámuel Komoly, Rita Weintraut, Kázmér Karádi, Norbert Kovács
Background. Female Parkinson's disease (PD) patients seem to experience not only more severe motor complications and postural instability but also more pronounced depression, anxiety, pain, and sleep disturbances. Objective. The aim of the present study was to evaluate the role of sex as a possible independent predictor of HRQoL in PD. Methods. In this cross-sectional study, 621 consecutive patients treated at the University of Pécs were enrolled. Severity of PD symptoms was assessed by MDS-UPDRS, UDysRS, Non-Motor Symptoms Scale, PDSS-2, Hamilton Anxiety Scale, Montgomery-Asberg Depression Rating Scale, Lille Apathy Rating Scale, and Addenbrooke Cognitive Examination...
2016: Parkinson's Disease
Christiana Ossig, Daniel Sippel, Mareike Fauser, Florin Gandor, Wolfgang H Jost, Georg Ebersbach, Alexander Storch
BACKGROUND: Since previous studies aimed to study nonmotor symptom (NMS) fluctuations in direct conjunction with motor oscillations, there are no data available on the temporal context of NMS fluctuations and motor oscillations in advanced Parkinson's disease (PD). OBJECTIVE: To evaluate circadian patterns and temporal connections of NMS and motor fluctuations in PD. METHODS: 15 controls, 17 non-fluctuating and 15 fluctuating PD patients completed two diaries by rating 4 key psychiatric (anxiety, depressive mood, inner restlessness, concentration/attention deficits), fatigue and 4 autonomic NMS (excessive sweating, sialorrhea, bladder urgency, dizziness) absent or present and motor function (Off, On with/without dyskinesia, and asleep) for every hour for 5 consecutive days...
May 31, 2016: Journal of Parkinson's Disease
Salim Yalcin Inan, Burak Cem Soner, Ayse Saide Sahin
Parkinson's disease (PD) is one of the most common neurodegenerative disorders, which affects more than six million people in the world. While current available pharmacological therapies for PD in the early stages of the disease usually improve motor symptoms, they cause side effects, such as fluctuations and dyskinesias in the later stages. In this later stage, high frequency deep brain stimulation of the subthalamic nucleus (STN-DBS) is a treatment option which is most successful to treat drug resistant advanced PD...
August 2016: Metabolic Brain Disease
Florence C F Chang, Vu Kwan, David van der Poorten, Neil Mahant, Nigel Wolfe, Ainhi D Ha, Jane M Griffith, David Tsui, Samuel D Kim, Victor S C Fung
We report the efficacy and adverse effect profile of intraduodenal levodopa-carbidopa intestinal gel (LCIG) infusion from patients treated in a single Australian movement disorder centre. We conducted an open-label, 12 month prospective study of treatment with LCIG in patients with advanced Parkinson's disease in a single tertiary referral hospital unit specialising in movement disorders. Patients with levodopa-responsive, advanced Parkinson's disease with motor fluctuations despite optimal pharmacological treatment were enrolled and underwent a 16 hour daily infusion of LCIG for 12 months...
March 2016: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
Hilary Highfield Nickols, Joannes P Yuh, Karen J Gregory, Ryan D Morrison, Brittney S Bates, Shaun R Stauffer, Kyle A Emmitte, Michael Bubser, Weimin Peng, Michael T Nedelcovych, Analisa Thompson, Xiaohui Lv, Zixiu Xiang, J Scott Daniels, Colleen M Niswender, Craig W Lindsley, Carrie K Jones, P Jeffrey Conn
Negative allosteric modulators (NAMs) of metabotropic glutamate receptor subtype 5 (mGlu5) have potential applications in the treatment of fragile X syndrome, levodopa-induced dyskinesia in Parkinson disease, Alzheimer disease, addiction, and anxiety; however, clinical and preclinical studies raise concerns that complete blockade of mGlu5 and inverse agonist activity of current mGlu5 NAMs contribute to adverse effects that limit the therapeutic use of these compounds. We report the discovery and characterization of a novel mGlu5 NAM, N,N-diethyl-5-((3-fluorophenyl)ethynyl)picolinamide (VU0477573) that binds to the same allosteric site as the prototypical mGlu5 NAM MPEP but displays weak negative cooperativity...
January 2016: Journal of Pharmacology and Experimental Therapeutics
Yukihiro Ohno, Saki Shimizu, Kentaro Tokudome, Naofumi Kunisawa, Masashi Sasa
Parkinson's disease (PD) is a common, late-onset neurodegenerative disorder that shows progressive extrapyramidal motor disorders (e.g., bradykinesia, resting tremors, muscle rigidity and postural instability) and various non-motor symptoms (e.g., cognitive impairment, mood disorders, autonomic dysfunction and sleep disorders). While dopaminergic agents such as L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine D2 agonists are widely used for the treatment of PD, there is still high clinical unmet need for novel medications that overcome the limitations of current therapies...
November 2015: Progress in Neurobiology
O S Levin
Buspirone, a nonbenzodiasepine anxiolytic, is a partial serotonin 5-HT1A-receptor agonist, D2-autoreceptor antagonist and low affinity 5-HT2-receptor agonist. This medication is used for treatment of generalized anxiety disorder though it may be prescribed in other anxiety states, primarily, panic disorder, sociophobia and depression. Buspirone seems to be potential in treatment of other neurological and mental disorders (tardive dyskinesia in Parkinson's disease, ataxia, behavioral disorders, cranial/brain injuries, dementia, attention-deficit hyperactivity disorder)...
2015: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
L Vahter, K Kannel, U Sorro, H Jaakmees, T Talvik, K Gross-Paju
Anti-NMDA-receptor encephalitis is an autoimmune disorder with a well-defined set of clinical features including psychiatric changes (anxiety, agitation, bizarre behaviour, delusional or paranoid thoughts), epileptic seizures and cognitive disturbance followed by movement disorders including orofacial dyskinesias, alterations in the level of consciousness and dysautonomia. Although the cognitive changes are not always very clear at presentation, they can persist after recovery from the acute and often prolonged illness...
July 2014: Oxford Medical Case Reports
Olivier Rascol, Santiago Perez-Lloret, Philippe Damier, Arnaud Delval, Pascal Derkinderen, Alain Destée, Wassilios G Meissner, Francois Tison, Laurence Negre-Pages
This study aimed at determining the prevalence of falling in PD patients, to assess generic and disease-specific clinical and pharmacological factors, relationship with health-related quality of life (HR-QoL) and changes in falls from OFF to ON in patients with motor fluctuations. Six-hundred and eighty-three PD patients of the COPARK survey were evaluated (11 had missing data and were excluded from the analysis). Patients with falls were identified as those with a UPDRS Item 13 ≥ 1 in the ON condition. All patients were assessed in a standardized manner [demographics, treatments, Unified PD Rating Scale (UPDRS), Hospital Anxiety and Depression Scale, Pittsburg questionnaire and HR-QoL scales (SF36, PDQ39)]...
October 2015: Journal of Neural Transmission
Per Svenningsson, Carl Rosenblad, Karolina Af Edholm Arvidsson, Klas Wictorin, Charlotte Keywood, Bavani Shankar, David A Lowe, Anders Björklund, Håkan Widner
In advanced stages of Parkinson's disease, serotonergic terminals take up L-DOPA and convert it to dopamine. Abnormally released dopamine may participate in the development of L-DOPA-induced dyskinesias. Simultaneous activation of 5-HT1A and 5-HT1B receptors effectively blocks L-DOPA-induced dyskinesias in animal models of dopamine depletion, justifying a clinical study with eltoprazine, a 5-HT1A/B receptor agonist, against L-DOPA-induced dyskinesias in patients with Parkinson's disease. A double-blind, randomized, placebo-controlled and dose-finding phase I/IIa study was conducted...
April 2015: Brain: a Journal of Neurology
Zoltan Hidasi, Pal Salacz, Eva Csibri
Movement disorders are common in psychiatry. The movement disorder can either be the symptom of a psychiatric disorder, can share a common aetiological factor with it, or can be the consequence of psychopharmacological therapy. Most common features include tic, stereotypy, compulsion, akathisia, dyskinesias, tremor, hypokinesia and disturbances of posture and gait. We discuss characteristics and clinical importance of these features. Movement disorders are frequently present in mood disorders, anxiety disorders, schizophrenia, catatonia, Tourette-disorder and psychogenic movement disorder, leading to differential-diagnostic and therapeutical difficulties in everyday practice...
December 2014: Neuropsychopharmacologia Hungarica
Georg Jaeschke, Sabine Kolczewski, Will Spooren, Eric Vieira, Nadia Bitter-Stoll, Patrick Boissin, Edilio Borroni, Bernd Büttelmann, Simona Ceccarelli, Nicole Clemann, Beatrice David, Christoph Funk, Wolfgang Guba, Anthony Harrison, Thomas Hartung, Michael Honer, Jörg Huwyler, Martin Kuratli, Urs Niederhauser, Axel Pähler, Jens-Uwe Peters, Ann Petersen, Eric Prinssen, Antonio Ricci, Daniel Rueher, Marianne Rueher, Manfred Schneider, Paul Spurr, Theodor Stoll, Daniel Tännler, Jürgen Wichmann, Richard H Porter, Joseph G Wettstein, Lothar Lindemann
Negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu5) have potential for the treatment of psychiatric diseases including depression, fragile X syndrome (FXS), anxiety, obsessive-compulsive disorders, and levodopa induced dyskinesia in Parkinson's disease. Herein we report the optimization of a weakly active screening hit 1 to the potent and selective compounds chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, 2) and 2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine (CTEP, 3)...
February 12, 2015: Journal of Medicinal Chemistry
Katherine H O Deane, Helen Flaherty, David J Daley, Roland Pascoe, Bridget Penhale, Carl E Clarke, Catherine Sackley, Stacey Storey
OBJECTIVES: This priority setting partnership was commissioned by Parkinson's UK to encourage people with direct and personal experience of the condition to work together to identify and prioritise the top 10 evidential uncertainties that impact on everyday clinical practice for the management of Parkinson's disease (PD). SETTING: The UK. PARTICIPANTS: Anyone with experience of PD including: people with Parkinson's (PwP), carers, family and friends, healthcare and social care professionals...
2014: BMJ Open
Yuh-Jiin I Jong, Ismail Sergin, Carolyn A Purgert, Karen L O'Malley
Although G protein-coupled receptors are primarily known for converting extracellular signals into intracellular responses, some receptors, such as the group 1 metabotropic glutamate receptor, mGlu5, are also localized on intracellular membranes where they can mediate both overlapping and unique signaling effects. Thus, besides "ligand bias," whereby a receptor's signaling modality can shift from G protein dependence to independence, canonical mGlu5 receptor signaling can also be influenced by "location bias" (i...
December 2014: Molecular Pharmacology
Laura J Bach
BACKGROUND: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an auto immune-disorder. It is a life threatening condition that typically presents with viral illness, headaches, severe psychiatric symptoms, seizures, behavioural changes, decreasing levels of unconsciousness and progressive unresponsiveness, cognitive impairment, abnormal movements (e.g., dyskinesia), ataxia and hypoventilation. OBJECTIVE: This paper describes the long term outcome and rehabilitation management of patients with NMDAR encephalitis and highlights the diverse outcome of this condition and the unique and individual long term management needs associated with this disorder...
2014: NeuroRehabilitation
M Ben Azoun, S Tatencloux, K Deiva, P Blanc
Although less frequent than viral encephalitis, anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a frequent form of acute pediatric encephalitis. After a prodromal phase of flu-like symptoms, psychiatric symptoms predominate - agitation, anxiety, hallucinations - and can make correct diagnosis more difficult. Also noted are abnormal dyskinesia and dystonia-like movements, partial seizures, difficulties talking or memorizing, and autonomic manifestations. The presentation of two cases of anti-NMDAR encephalitis illustrates the symptoms of this disease...
November 2014: Archives de Pédiatrie: Organe Officiel de la Sociéte Française de Pédiatrie
Peter Jenner
Adenosine A2A receptor antagonists represent a new way forward in the symptomatic treatment of Parkinson's disease (PD) through a non-dopaminergic mechanism. As a class, adenosine A2A antagonists are effective in reversing motor deficits in haloperidol-treated rodents, 6-OHDA-lesioned rats, and MPTP-treated primates when combined with low doses of l-dopa or dopamine agonist drugs. Importantly, they improve motor function without worsening dyskinesia and they may prevent the onset of involuntary movements. Adenosine A2A receptor antagonists are active in animal models of reduced cognition, anxiety, and depression and so this drug class may also be effective in controlling the neuropsychiatric components of nonmotor symptoms in PD...
2014: International Review of Neurobiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"